4786-75-8

Usage

Uses

Used in Medicinal Chemistry:
4-(benzylsulfanyl)-7H-pyrrolo[2,3-d]pyrimidine is used as a scaffold in drug discovery and development for its potential to form biologically active molecules. Its unique structure and properties make it a valuable building block for designing new pharmaceutical compounds.
Used in Drug Discovery and Development:
In the pharmaceutical industry, 4-(benzylsulfanyl)-7H-pyrrolo[2,3-d]pyrimidine is utilized as a starting point for creating new drugs. Its derivatives have shown promising pharmacological activities, which makes it a subject of interest for further research and development aimed at treating a range of diseases.
Used in Research and Development:
4-(benzylsulfanyl)-7H-pyrrolo[2,3-d]pyrimidine is employed in research settings to explore its potential applications and to develop new therapeutic agents. Studies on its derivatives have demonstrated their effectiveness, spurring ongoing interest in 4-(benzylsulfanyl)-7H-pyrrolo[2,3-d]pyrimidine for advancing medicinal chemistry.

Upstream product

• 100-53-8 phenylmethanethiol 
• 3680-69-1 4-chloro-1H-pyrrolo[2,3-d]pyrimidine 

Downstream Products

• 945950-11-8 (4aS,6R,7S,7aR)-6-[4-(Benzylsulfanyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-2-(4-methoxyphenyl)hexahydrocyclopenta[d][1,3]dioxin-7-ol 

Relevant academic research and scientific papers

Targeting nuclear protein TDP-43 by cell division cycle kinase 7 inhibitors: A new therapeutic approach for amyotrophic lateral sclerosis

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with no known cure. Aggregates of the nuclear protein TDP-43 have been recognized as a hallmark of proteinopathy in both familial and sporadic cases of ALS. Post-translational modifications of this protein, include hyperphosphorylation, cause disruption of TDP-43 homeostasis and as a consequence, promotion of its neurotoxicity. Among the kinases involved in these changes, cell division cycle kinase 7 (CDC7) plays an important role by directly phosphorylating TDP-43. In the present manuscript the discovery, synthesis, and optimization of a new family of selective and ATP-competitive CDC7 inhibitors based on 6-mercaptopurine scaffold are described. Moreover, we demonstrate the ability of these inhibitors to reduce TDP-43 phosphorylation in both cell cultures and transgenic animal models such as C. elegans and Prp-hTDP43 (A315T) mice. Altogether, the compounds described here may be useful as versatile tools to explore the role of CDC7 in TDP-43 phosphorylation and also as new drug candidates for the future development of ALS therapies.

Inhibitors of E1 activating enzymes

This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.